The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl36475 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Junhui Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, 261061 Weifang, Shandong, China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Cell Differentiation, Adenosine, Immunomodulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mesenchymal stem cells (MSCs) are widely utilized in tissue repair, anti-inflammatory treatment, and cell therapy due to their remarkable multidirectional differentiation potential, immunosuppressive capabilities, and low immunogenicity. However, the regulatory mechanisms underlying their functions are intricate, and epigenetic modifications are a significant contributing factor. N6-methyladenosine (m6A) modification affects the proliferation, differentiation, and immunomodulation of MSCs by regulating the stability, transport, and translation of RNA. Studies have shown that m6A modification promotes osteogenic differentiation through the bone morphogehetic protein/small mothers against decapentaplegic (BMP/Smad) and wingless-related integration site/β-catenin (Wnt/β-catenin) pathways. It also enhances the anti-inflammatory effect of MSCs by modulating immune cell polarization and the release of inflammatory mediators. Moreover, exosomes secreted by MSCs contribute to immunomodulation and the response to cancer treatment by regulating the m6A modification of genes in target cells. “Writers” of m6A, such as methyltransferase-like 3 (METTL3) and METTL14, and “erasers”, such as fat mass and obesity-associated protein (FTO) and alkB homolog 5 (ALKBH5), are crucial in regulating the functions of MSCs. Targeting m6A modification via the clinical application of MSCs may represent a new cancer treatment strategy. Therefore, a comprehensive investigation of the m6A regulatory mechanism is essential. This review provides theoretical and technical support for the clinical use of MSCs, facilitating the development of more effective therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, 261061 Weifang, Shandong, China.
- School of Basic Medicine Sciences, Shandong Second Medical University, 261053 Weifang, Shandong, China.
Zitieren
APA
Zhao, J., Zhang, X., Wang, Y., Zeng, Y., Sun, H., & Cui, X. (2025). The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl36475
Vancouver
Zhao J, Zhang X, Wang Y, Zeng Y, Sun H, Cui X. The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl36475
BibTeX
@article{Zhao2025,
author = {Zhao, Junhui and Zhang, Xiaoyun and Wang, Yanhui and Zeng, Yu and Sun, Hongliang and Cui, Xiaodong},
title = {The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl36475}
}
EUVIMED